Patent Claims Must Be Written Narrowly, Federal Circuit Reaffirms In Ariad v. Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
Ruling in favor of Lilly, an en banc panel finds that the requirement that patent claims provide an adequate written description of an invention is separate from enabling someone to use the invention.
You may also be interested in...
PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial
Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.
Lilly Laid Groundwork For Abbott's Defeat Of J&J's Patent Verdict On Humira
Abbott Laboratories had reason to thank Eli Lilly & Co. when the U.S. Court of Appeals for the Federal Circuit overturned a record $1.67-billion jury verdict that Abbott's Humira infringed a Johnson & Johnson patent.